Ventyx Biosciences Inc. (NASDAQ: VTYX)
$2.92
+0.0800 ( +2.82% ) 218.7K
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Market Data
Open
$2.92
Previous close
$2.84
Volume
218.7K
Market cap
$205.51M
Day range
$2.79 - $3.03
52 week range
$1.87 - $38.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4/a | Other | 1 | Aug 04, 2023 |
4 | Insider transactions | 1 | Aug 04, 2023 |
4 | Insider transactions | 1 | Aug 04, 2023 |
4 | Insider transactions | 1 | Aug 01, 2023 |
4 | Insider transactions | 1 | Aug 01, 2023 |
4 | Insider transactions | 1 | Aug 01, 2023 |
4 | Insider transactions | 1 | Jul 26, 2023 |
8-k | 8K-related | 13 | Jul 26, 2023 |
4/a | Other | 1 | Jul 19, 2023 |
4/a | Other | 1 | Jul 19, 2023 |